EPCAM and neoplasm: Although an ongoing open-label, multicenter trial evaluating an EpCAM CAR-T cell therapy (IMC001) has reported encouraging early-term results in patients with advanced GC and colorectal cancer25, the potential risk of severe off-tumor toxicities remains a significant concern26.